Friday December 6, 2013 0 commentsCENTENNIAL - Cochlar Limited (ASX: COH), the global leader in implantable hearing solutions, announced the U.S. Food and Drug Administration has cleared its Baha 4 Attract System for use in the U.S.
Cochlear said it is now the only company to offer patients a choice of either a magnetic or a direct bone conduction hearing solution.
"The Baha 4 Attract System sets new standards in simplicity, comfort and hearing performance for magnetic bone conduction implant systems," said Chris Smith, president of Cochlear Americas.
"We are pleased to be bringing this new hearing option to patients who want to enjoy the benefits of the Baha System without a skin-penetrating abutment. Cochlear is dedicated to being a leader in bone conduction and this important milestone further emphasizes our commitment to continuing our legacy in innovation."
The Baha 4 Attract System uses magnets to connect the sound processor to the titanium implant, Cochlear said. The sound process attaches to the external magnet, which transmits the sound to the internal magnet hidden under the skin.
The first Baha 4 surgeries in the U.S. began Nov. 26, and so far about 100 people have been implanted with the device worldwide.